Lim SL, et al. - Since the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to neoadjuvant chemotherapy (NACT) for stage III epithelial ovarian cancer (EOC) in a recent randomized controlled trial showed an overall survival benefit, researchers quantified the cost-effectiveness of HIPEC in this setting. For stage III epithelial ovarian cancer, HIPEC in addition to interval cytoreduction increases the cost of care. Adding HIPEC to stage III epithelial ovarian cancer at cytoreduction intervals is cost-effective. At interval cytoreductive surgery (ICS), the ICER for HIPEC is $2436/quality-adjusted life year vs ICS alone, which is far below the accepted threshold. According to findings, ICS + HIPEC is the cost-effective management of stage III EOC when performing NACT.